Menu

Editas Medicine, Inc. EDIT

Full chart Compare
Set alert

Price alert · EDIT

All alert types
2.57 USD +0.02 (+0.78%)

At closeNov 6, 2026, 6:37 PM EST

2.57 0.00 0.00%

After hours · Nov 6, 6:37 PM ET

2.48 Day range 2.63
1.66 52-week range 3.75
YTD
+25.37%
1 year
-4.46%

Discussion (212)

Sign in to join the discussion

Vivian O'Neal EDIT 6 years ago #41

Please read the press release surrounding today’s topic. The company is moving “full steam ahead” with CTX-110. The patient who passed:

Patient characteristics: 72-year-old male with relapsed transformed follicular lymphoma following five prior lines of therapy, including autologous stem cell transplant
Efficacy: Complete response on Day 25 post infusion of CTX110
Safety:

  • Experienced Grade 2 CRS at Day 5 that resolved
  • Admitted with febrile neutropenia at Day 26 and developed confusion and memory loss starting at Day 28, with further deterioration ultimately requiring intubation for airway protection
  • Initially treated for ICANS and later found to have reactivation of HHV-6 and HHV-6 encephalitis
  • Despite treatments, patient remained obtunded and died on Day 52 after family requested withdrawal of further treatment
Vivian O'Neal EDIT 6 years ago #42

It is my humble opinion that this is a chance for edit to take the lead here. CRSP was speeding imho. Slow and steady wins the race always,

Vivian O'Neal EDIT 6 years ago #43

It is all about who is further along in trials and how many. Truth is there is a lot of room here for many players. Best in class is will prevail for now we are in second and could end up in first with the blink of an eye.

Vivian O'Neal EDIT 6 years ago #44

From a technical view looks like the stock is set to break out and take out $40 and possibly $50

Vivian O'Neal EDIT 6 years ago #46

Albright got his beak wet for the season nice little $100K in his pocket. We are only $10+ from all time high that could happen in 2-3 sessions

Vivian O'Neal EDIT 6 years ago #47

This sector will be hotter then the EV sector is right now this time next year. EDIT and CRSP have Phase1/2 data due soon very soon that will bring the attention needed it is my opinion the focus will shift to EDIT for LCA10 and could very well push us into the lead price wise market cap whatever

Vivian O'Neal EDIT 6 years ago #48

The reality of this whole situation is that you can bet this

Vivian O'Neal EDIT 6 years ago #50

The longer the base the higher in space....time for blast off